Compare Las Vegas Sands Corp. (LVS) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs Regeneron Pharmaceuticals Inc — how do they compare? Las Vegas Sands Corp. trades at $45.83 (market cap $29.44B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.8× Las Vegas Sands Corp.'s market cap, and Las Vegas Sands Corp. pays the higher dividend (2.64%). Which is the better fit depends on your goals.
| LVS | REGN | |
|---|---|---|
Market Cap | $29.44B | $82.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $812.27 |
52-Week Low | $44.78 | $555.51 |
Enterprise Value | $41.33B | $76.77B |
Dividend Yield | 2.64% | 0.47% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
